Immunome (IMNM) reported a 2024 net loss Wednesday of $5 per diluted share, narrowing from the loss of $5.38 a year earlier.

Analysts polled by FactSet expected a loss of $4.38.

Collaboration revenue fell to $9.04 million from $14 million a year earlier.

Analysts surveyed by FactSet expected $9.4 million.

As of Dec. 31, the company had cash, cash equivalents and marketable securities of $217.3 million, excluding gross proceeds of $172.5 million from financing in January, the company said. The current cash runway is expected to extend into 2027.